A5084592602- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatitis Viruses Studies and Epidemiology
- Systemic Lupus Erythematosus Research
- Drug-Induced Hepatotoxicity and Protection
- Renal Transplantation Outcomes and Treatments
- Vasculitis and related conditions
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Viral Infections and Immunology Research
- Eosinophilic Disorders and Syndromes
- Organ Transplantation Techniques and Outcomes
- IgG4-Related and Inflammatory Diseases
- Liver physiology and pathology
- Viral gastroenteritis research and epidemiology
- Inflammatory Bowel Disease
- Heparin-Induced Thrombocytopenia and Thrombosis
- Plant Disease Management Techniques
- Immunodeficiency and Autoimmune Disorders
- Polyomavirus and related diseases
Intercept Pharmaceuticals (United States)
2021-2022
Universitat de Barcelona
2016-2019
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2015-2019
Hospital Clínic de Barcelona
2015-2018
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2018
Centro de Investigación Biomédica en Red
2016-2018
Hospital Italiano de Buenos Aires
2010
Leiden University Medical Center
2010
Nonalcoholic steatohepatitis (NASH) affects patients' health-related quality of life (HRQoL). Patient-reported outcomes (PROs) evaluating HRQoL were assessed in the RandomizEd Global Phase 3 Study to Evaluate Impact on NASH with FibRosis Obeticholic Acid TreatmEnt (REGENERATE) study, which showed that obeticholic acid (OCA) significantly improved fibrosis patients NASH. Noncirrhotic a phase 3, double-blind, randomized, placebo-controlled, multicenter, international study OCA enrolled. The...
Summary Background Grey Zone ( GZ ) is an ill‐defined situation including patients falling between inactive carrier IC state and HB eAg‐negative chronic hepatitis B CHB ). Aims To assess the long‐term outcomes of compared to in absence treatment. Methods Retrospective analysis 287 patients. Patients were classified into 4 groups at baseline: HBV ‐ DNA <2000 IU/mL ALT <40 U/L ), IU / mL 40‐80 ‐1), 2000‐20 000 ‐2) or ‐3). Data also analysed using AASLD criteria. Results After a median...
Summary Background A few cases of hepatitis B virus ( HBV ) reactivation during anti‐viral therapy against C HCV have been reported. However, the information regarding real impact this phenomenon is scarce. Aim To evaluate risk with an interferon‐free regimen direct‐acting anti‐virals DAA s). Methods Observational and prospective study 352 patients receiving s between September 2015 May 2016. ‐ DNA ALT levels were monitored at baseline, week 4 therapy, end treatment 12 weeks after...
Summary In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir ( EBR / GZR ) demonstrated high cure rates and a good safety profile. This study assessed the effectiveness , without ribavirin, in real‐world patient cohort. HEPA ‐C is collaborative, monitored national registry directed by Spanish Association for Study Liver Networked Biomedical Research Centre Hepatic Digestive Diseases. Patients entered into between December 2016 May 2017, treated at...
Abstract Background & Aims The combination of hepatitis B immunoglobulin and a nucleos(t)ide analogues has markedly reduced the rate virus recurrence after liver transplantation; however, optimal duration not been clarified. This lack consensus perpetuates use different strategies. aim this study was to evaluate risk factors associated transplantation in large cohort patients under regimens. Methods Retrospective multicentre analysis virus‐related recipients receiving combined...
Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes this event are unknown. We hypothesized that PIs might impair innate immune responses through inhibition proteases participating anti-bacterial functions neutrophils and monocytes. The aims study were to assess phagocytic oxidative burst capacity monocytes obtained from PI...
Casciato, P. C.; Bonacci, M.; Surraco, M. P.; Orozco, F.; Piñero, Villamil, A. G.; Marciano, S.; Bandi, J. Galdame, O. A.; Gadano, C. Author Information